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Genome-wide copy-number variation study of psychosis in
Alzheimer’s disease
X Zheng1,2, FY Demirci3, MM Barmada3, GA Richardson4,5, OL Lopez6,7, RA Sweet4,6,7, MI Kamboh3,4,5 and E Feingold1,3
About 40–60% of patients with late-onset Alzheimer’s disease (AD) develop psychosis, which represents a distinct phenotype of
more severe cognitive and functional deficits. The estimated heritability of AD+P is ~ 61%, which makes it a good target for genetic
mapping. We performed a genome-wide copy-number variation (CNV) study on 496 AD cases with psychosis (AD+P), 639 AD
subjects with intermediate psychosis (AD intermediate P) and 156 AD subjects without psychosis (AD− P) who were recruited at the
University of Pittsburgh Alzheimer's Disease Research Center using over 1 million single-nucleotide polymorphisms (SNPs) and CNV
markers. CNV load analysis found no significant difference in total and average CNV length and CNV number in the AD+P or AD
intermediate P groups compared with the AD− P group. Our analysis revealed a marginally significant lower number of duplication
events in AD+P cases compared with AD− P controls (P= 0.059) using multivariable regression model. The most interesting finding
was the presence of a genome-wide significant duplication in the APC2 gene on chromosome 19, which was protective against
developing AD+P (odds ratio = 0.42; P= 7.2E− 10). We also observed suggestive associations of duplications with AD+P in the SET
(P= 1.95E− 06), JAG2 (P= 5.01E− 07) and ZFPM1 (P= 2.13E− 07) genes and marginal association of a deletion in CNTLN
(P= 8.87E− 04). We have identified potential novel loci for psychosis in Alzheimer’s disease that warrant follow-up in large-scale
independent studies.
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INTRODUCTION
Alzheimer's disease (AD), especially the late-onset form, is the
leading cause of dementia among older persons. Twin studies
have shown that genetic factors have an important role in
explaining AD with up to 79% heritability.1 Beyond the well-
established apolipoprotein E association, several susceptibility loci
have been identified by large-scale genome-wide association
studies.2–15 However, single-nucleotide polymorphisms (SNPs) at
all those loci explain o50% of AD heritability.
To identify additional genetic factors related to AD, genome-
wide scans for copy-number variants (CNVs) have been conducted
recently.16–24 Swaminathan et al.18 reported a trend for reduced
levels of deletions and duplications in AD cases compared with
controls; whereas Ghani et al.20 found no significant differences
between cases and controls in CNV rate, distribution of deletions
or duplications, total or average CNV size or number of genes
affected by CNVs, except for a nominal association between AD
and a duplication on 15q11.2. Chapman et al.22 reported a limited
contribution of rare CNVs to AD risk, but proposed that healthy
elderly individuals have a reduced rate of large deletions. The
inconsistent genome-wide CNV findings in AD may partially be
due to its heterogeneous nature.
About 40–60% of late-onset AD patients will develop psychosis.
AD+P has more severe cognitive and functional deficits. It
has more rapid deterioration than AD without psychosis
and represents a distinct phenotype with a genetic basis. The
estimated heritability of AD+P is about 61%;25 however the
genetic variants that explain this high heritability are unknown.
The first genome-wide association study of AD+P was performed
recently by Hollingworth et al.26 They have identified several
suggestive loci that were associated with AD+P when compared
with AD− P and/or general population, but none of them were
genome-wide significant. To systematically identify the genetic
variants that account for additional heritability of AD+P, we
conducted a genome-wide CNV study of AD+P using the Illumina
HumanOmni1-Quad BeadChip (San Diego, CA, USA).
MATERIALS AND METHODS
Subjects
Subjects were participants in a study on the genetics of AD, which
recruited 1440 AD cases (mean age-at-onset 72.6 ± 6.4 years) through the
University of Pittsburgh Alzheimer's Disease Research Center and 1000
older controls (mean age 74.07 ± 6.20 years). All the participants were
examined with detailed clinical, laboratory and neuroimaging
evaluations.27,28 Data from 1291 AD patients that passed stringent quality
control criteria from our previous genome-wide study2 were used in this
study. Subjects with AD met criteria for either probable or definite AD
according to criteria set by the National Institute of Neurological and
Communicative Disorders and Stroke–Alzheimer’s disease and Related
Disorders Association and the Consortium to Establish a Registry for
Alzheimer’s disease.29 Subjects with evidence of persistent and or
recurrent delusions or hallucinations, defined by the Consortium to
Establish a Registry for Alzheimer’s disease behavior rating scale30 items for
psychotic features (items 33–35) rated as occurring three or more times in
the past month at any visit, were classified as AD+P, as previously
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described.31 Subjects with evidence of infrequent distortions of thought or
perception, defined by any of these items rated as occurring one to two
times in the past month, were classified as ‘indeterminate psychosis’ as
such symptoms can result from a variety of sources. Subjects rated as no
occurrence of possible psychotic symptoms at all visits were classified as
AD− P. Subjects were excluded if they had a previous history of
schizophrenia (SCZ) or bipolar disorder. Details on the study population
characteristics can be found elsewhere.2,26 Among the 1291 AD subjects,
496 were classified as AD+P, 639 as AD with ‘indeterminate’ psychosis and
156 as AD− P. Because the ‘indeterminate’ group is actually an
‘intermediate’ group and not an ‘unknown’ group, we include them in
this study to increase statistical power.
Illumina assay for CNV discovery
All subjects were genotyped using the high-throughput genome-wide SNP
Illumina HumanOmni1-Quad BeadChip (containing 1 016 423 SNPs and/or
CNVs).2 We generated CNV calls using the PennCNV software (2009 Aug27
version).32 PennCNV is a Hidden Markov Model (HMM)-based method. It
uses the log R ratio (LRR) and B allele frequency (BAF) measures computed
from the signal intensity files by Beadstudio to detect the CNVs. The
simultaneous analysis of intensity data and genotype data in the same
experimental setting generated high accurate definition of normal diploid
states and any deviation from norm.
CNV quality control
Details on the quality control parameters applied on the samples and
markers have been described previously.2,26 Criteria for exclusion of
samples included the consent and diagnostic criteria, high genotyping
failure rate and/or cryptic relatedness. Briefly, only samples with call rates
498% were retained. Samples were filtered if mean X-chromosome
heterozygosity ⩾ 0.02 for males or outside the range of 0.25~ 0.4 for
females. Genetic outliers and those with evidence of relatedness (IBD
estimate ⩾ 0.4) or non-European ancestry based on genotype data were
also excluded. After filtering, 496 AD+P cases, 639 AD intermediate P, 156
AD− P controls were retained. Markers were excluded if they had a
genotype missing rate of 40.02. Markers were examined to determine
whether missingness depended on case/control status or the genotyping
batch. To call CNVs, we used the GC model wave adjustment procedure in
PennCNV to smooth out genomic waving, since wave artifacts correlating
with GC content and resulting from hybridization bias of low full-length
DNA quantity can interfere with the accurate inference of CNVs. After GC
model adjustment, we filtered the samples that met the criterion of LRR
standard deviation ⩾ 0.3, and |GC base pair wave factor|40.05. About 10%
of all samples (122 subjects) were further removed. A total 440 AD+P cases,
593 AD intermediate P, 136 AD− P controls were used in the final analysis.
Additional QC was applied at the CNV level by excluding CNV calls o5 kb
in length and spanning o5 probes.33 All procedures followed the user
Table 1. Descriptive characteristics for all samples
AD+P AD int P AD− P
n 496 639 156
% Female 66.9 60.9 59
Age at onset, mean (s.d.) 73.1 (6.2) 72.4 (6.8) 73.4 (6.3)
Age at interview/ascertainment,
mean (s.d.)
76.9 (5.8) 73.3 (7.3) 76.4 (5.8)
Abbreviations: AD, Alzheimer's disease; Int, intermediate; P, psychosis.
Table 2. Overall CNV burden
All CNVs Deletion Duplication
Betaa P-value Beta P-value Beta P-value
Univariable model
Total CNV length
AD−P (Intercept)b 3 435 056 REFc 1 660 365 REF 1 774 691 REF
AD Int P 700 671 0.303 214 836 0.439 485 835 0.421
AD+P 348 967 0.619 196 205 0.494 152 761 0.806
Average CNV length
AD−P (Intercept) 38 577 REF 27757 REF 64 762 REF
AD Int P 3951 0.314 473 0.702 4800 0.623
AD+P 1183 0.77 125 0.922 7344 0.466
Number of CNVs
AD−P (Intercept) 75.9 REF 56.1 REF 19.7 REF
AD Int P 1.9 0.674 − 0.9 0.844 2.7 0.093
AD+P 0.8 0.863 3.8 0.393 − 3 0.072
Multivariable model (adjustment of sex, age, first four principal components of population structure)
Total CNV length
AD−P (Intercept) — REF — REF — REF
AD Int P 639 309 0.347 219 210 0.429 420 099 0.487
AD+P 24 455 0.696 196 762 0.492 77 693 0.901
Average CNV length
AD−P (Intercept) — REF — REF — REF
AD Int P 3632 0.355 538 0.664 3575 0.714
AD+P 783 0.847 187 0.884 5810 0.564
Number of CNVs
AD−P (Intercept) — REF — REF — REF
AD Int P 1.7 0.701 − 0.9 0.838 2.6 0.112
AD+P 0.7 0.88 3.9 0.386 − 3.2 0.059
Abbreviations: AD, Alzheimer's disease; CNV, copy-number variant; Int, intermediate; P, psychosis. aThe coefficients for the other two groups are the differences
in the mean between the reference group and the other groups. bThe intercept in univariable model is the mean CNV load of the reference group. cAD− P
group was treated as reference group.
Genome-wide CNV study of AD+P
X Zheng et al
2
Translational Psychiatry (2015), 1 – 9
guidelines of PennCNV. Table 1 summarizes the number of samples in
different categories after quality control measures.
Statistical analysis of CNVs
Complex CNV overlap is simplified by producing SNP-based statistics. The
CNV frequencies between groups were compared at each SNP using an
ordered logistic regression model. Psychosis status was treated as an
ordered categorical outcome: AD− P, AD with intermediate psychosis and
AD+P. The predictor was CNV states. Copy number = 2 per individual was
considered normal. Deletion and duplication CNVs were defined as CNV
calls with copy number o2 and 42, respectively. Deletion and
duplication CNVs and normal copy number were coded as separate
variables (that is, categorical model with three categories). To adjust for the
confounding effect of population stratification, the first four principal
components of population structure were included as covariates in the
regression model. Age was also adjusted for.
Multiple testing was corrected using the Benjamini–Hochberg false
discovery rate. We reported associations with false discovery rate o0.01.
We reported statistical local minimums to narrow the association in
reference to a region of nominal significance. Regions of significance
ranging within a power of 10 are reported, as previously described.34 The
resulting nominally significant CNV regions were excluded if they met
either of the following criteria: (i) residing on telomere- or centromere-
proximal cytobands; (ii) located in a 'peninsula' of common CNVs arising
from variation in boundary truncation of CNV calling. Statistical
comparisons were performed only for CNV events observed on autosomes,
due to the complexity of analyzing the X and Y chromosomes. All data
analyses were conducted in R (version 3.0.1).35 Manhattan plots were used
to show the genome-wide P-values at each marker. As a final step to
confirm the validity of events with significantly frequency differences, LRR
and BAF plots were visually inspected to ensure that called CN gains and
losses were visually evident and not simply artifacts of the calling
algorithm. Human NCBI Build 36 (hg18) was used for assigning
chromosome locations.
CNV load
For each individual, we also defined several measures of autosomal
genomic CNV burden and compared mean values between phenotypic
groups. CNV burden for each individual was defined in three distinct ways;
(1) the total length of genomic DNA involved in identified CNV events; (2)
average length of CNVs; and (3) total number of CNVs. Comparison of CNV
burden among the groups was conducted using linear regression in R. The
outcomes were CNV burdens, the predictor was three AD groups, which




Clinical characteristics of the sample can be found in Table 1. We
calculated the overall CNV burden including total CNV length,
Figure 1. Manhattan plot shows the genome-wide P-values for duplication CNVs associated with AD+P. This Manhattan plot demonstrates the
locations across the chromosomes of the human genome (horizontal axis) where associations between duplication calls at markers (dots) and
AD+P are shown using − log10 P-values (vertical axis). The higher the dots are, the stronger the genetic associations are. The strongest signal is
seen on chromosome 19. AD, Alzheimer's disease; CNV, copy-number variant; P, psychosis.
Genome-wide CNV study of AD+P
X Zheng et al
3
Translational Psychiatry (2015), 1 – 9
average CNV length and number of observed CNV events in each
group of samples and also stratified copy number into duplica-
tions and deletions. Comparison of total and average CNV length
and CNV number revealed no significant difference in the AD+P or
AD intermediate P groups compared with the AD− P groups
(reference level), as seen in Table 2. In the univariate model,
average number of duplication events in AD− P subjects was 19.7,
compared with them, average number of duplication events in AD
Figure 2. Examples of duplication on chr 19 in one CNV carrier (a) and one non CNV subject (b), and examples of deletion on chr 9 in one CNV
carrier (c) and one non CNV subject (d) based on LRR and BAF. Each data point in the plots is a single marker (SNP or CNV marker). The x axis
shows marker’s base pair position on chromosome 19, based on Human NCBI Build 36 (hg18). For each subject, the y axis on the top panel is
the intensity data termed LRR and the bottom panel is the genotype data termed BAF. (a) Chromosome 19 duplication carrier. In the LRR plot,
the expected log2R ratio is zero for normal copy of autosomes; increases in log R ratio were observed in arrowed region; in the BAF plot, the
values at 0, 1/2 and 1 represent the expected positions of disomic AA, AB and BB genotypes, respectively. For a hemizygous duplication with
copy number of 3, it would have a wider BAF split (at 1/3 and 2/3). However, BAF values at 1/3 and 2/3 were not observed in this case because
this region is composed of homozygous SNP markers and a lot of CNV markers. (b) Subject without duplication. In the LRR plot, the arrowed
region has LRR around zero; in the BAF plot, the values were clustered around 0, 1/2 and 1 as expected for normal copy number. (c)
Chromosome 9 deletion carrier. In the LRR plot, the expected log2R ratio is zero for normal copy of autosomes; decreases in log R ratio were
observed in arrowed region; in the BAF plot, the values at 0, 1/2 and 1 represent the expected positions of disomic AA, AB and BB genotypes,
respectively. For a hemizygous deletion with copy number of 1, the BAF value on 1/2 disappeared. (d) Subject without chr 9 deletion. In the
LRR plot, the arrowed region has LRR around zero; in the BAF plot, the values were clustered around 0, 1/2 and 1 as expected for normal copy
number. BAF, B allele frequency; CNV, copy-number variant; LRR, log R ratio; SNP, single-nucleotide polymorphism.
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+P subjects was marginally significantly lower (beta coefficient =
− 3.0, P= 0.072); average number of duplications was still lower in
AD+P than in AD− P (beta coefficient =− 3.2, P= 0.059) group in
the multivariable model even after adjusting for age, sex and the
first four principal components of population substructure.
CNV association analyses
Duplication CNVs. We conducted a genome-wide scan for CNVs
associated with AD+P. The genome-wide P-values for duplication
CNVs are shown in a Manhattan plot (Figure 1). We identified a
duplication CNV on chromosome 19 that was genome-wide
significantly protective against AD+P (odds ratio = 0.42,
P= 7.20E− 10 for the test based on ordered logistic regression).
Forty-three out of 440 AD+P subjects carried this duplication
(frequency = 9.8%), while 172 out of 593 AD intermediate P and 33
out of 126 AD− P subjects had this duplication (frequency = 29.0
and 24.3%, respectively). Although the duplication frequency is
slightly higher in the intermediate group than in the AD− P
subjects, the two groups are very similar and we interpret this
departure from an ordered model as a function of the small
sample size. It is worth noting that this result was highly significant
even under the ordered model that we fit. This was a hemizygous
duplication (copy number of 3). It was located on chromosome
19p13.3 and affected only one gene, APC2 (adenomatosis
polyposis coli 2). Examples of this duplication in one CNV carrier
and one subject without CNV based on LRR and BAF are shown in
Figure 2. In addition, we detected four other duplications in which
frequency was significantly lower (Po1.0E− 05) in AD+P cases
compared with non AD+P subjects. One was located on
Figure 2. Continued.
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chromosome 16 and affected the ZFPM1 (zinc finger protein, FOG
family member 1) gene; for those who carry the duplication, the
odds of being AD+P versus non AD+P was 0.44 times lower than
for those without this duplication (P= 2.13E− 07). The second
duplication was located on chromosome 14 and affected the JAG2
(jagged 2) gene; the odds ratio of having AD+P in CNV carriers
versus non-carriers was 0.43 (P= 5.01E− 07). The third duplication
was on chromosome 9 and affected the SET (SET nuclear
oncogene) gene; the AD+P odds ratio was 0.44 (P= 1.95E− 06)
in CNV carriers. The fourth duplication was on chromosome 17
with AD+P odds ratio of 0.49 (P= 4.25E− 06) and affected no
known genes. Detailed information on all five AD+P associated
duplications is provided in Table 3.
Deletion CNVs. A Manhattan plot showing genome-wide P-values
for association of AD+P with deletion CNVs is presented in
Figure 3. None of the deletions is genome-wide significantly
associated with AD+P. However, we identified two deletions that
showed a marginal association with AD+P (Po1.0E− 3). One was
located on chromosome 4, which was more frequent in AD+P
subjects (26.1%) than in AD intermediate P (19.6%) and AD− P
(12.5%) subjects. There were no known genes in this deletion
region. Another deletion we identified was located on chromosome
9p22.2 and was present only in AD+P subjects (P=8.87E− 04); none
of AD intermediate P or AD− P subjects had this deletion. This was
a hemizygous deletion (copy number=1) and it affected only one
gene, CNTLN (centlein, centrosomal protein). Detailed information
on these two deletions is given in Table 3. Examples of this deletion
in one CNV carrier and one subject without CNV based on LRR and
BAF are shown in Figure 2.
DISCUSSION
Here we report the first genome-wide CNV study of AD+P. We
detected a genome-wide significant association between a
duplication and AD+P. This hemizygous duplication (copy number
of 3) covers the APC2 (adenomatous polyposis coli 2) gene on
chr1913.3 and is protective against developing AD+P (odds
ratio = 0.42, P= 7.2E− 10). The frequency of this duplication was
10% in AD+P compared with 29% in AD subjects with
intermediate P and 24% in AD− P. Previously, a large duplication
in this region on chr 19 containing APC2 has been reported at 26%
in healthy white males,36 which is similar to what we have
observed in subjects with intermediate P and in AD− P.
APC2, also called APCL, closely resembles APC in its overall
domain structure and function.37 It is primarily expressed in the
central nervous system and spans a genomic region over 20 kb.
APC2 is expressed specifically and abundantly in brain.38 APC2
protein could bind to beta-catenin and deplete the intracellular
beta-catenin pool,38 suggesting that APC2 may participate
in the regulation of neuronal functions in association with
beta-catenin. The Wnt (wingless)/β-catenin signaling pathway
has been involved in a multitude of neuronal processes,
including regulation of synaptogenesis, synapse specificity, axon
guidance, dendrite development and overall brain development.39
Wnt/β-catenin signaling pathway has been implicated in the
pathogenesis of several neurodevelopmental disorders, including
SCZ, bipolar disorder and autism spectrum disorders,40 while
psychosis is a key feature of SCZ and present in many cases of
bipolar disorder. It has been demonstrated that altered
levels and/or phosphorylation states of β-catenin and GSK-3 in
brain are related with SCZ and may represent susceptibility
loci for SCZ.41,42 Furthermore, it has been suggested that
changes in β-catenin and GSK-3 may represent one of the
mechanisms through which antipsychotics are able to exert
behavioral changes.43 It is possible that altered expression level of
APC2 affects the development of psychosis through Wnt
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Besides the interaction with β-catenin, animal models suggest
that APC2 could have a role in AD. Kuczera et al. (2010)44 analyzed
the effect of APC2 deletion on AD using a mouse model. They
found that although loss of APC2 did not affect the course of
pathology in an AD, APC2 cKO mice displayed impaired spatial
memory and severely impaired extinction of fear memories. They
further proposed that the mechanisms by which amyloid-β-
pathology and loss of APC2 affect memory function might share
similar mechanism of action. It is unclear whether this mechanism
is related to the critical role of APC2 in axonal projection and the
cytoskeletal regulation at leading edges in response to extra-
cellular signals.45,46 It is interesting to note that APC2 is associated
with susceptibility to SCZ.47 Accumulated evidence has shown
that many common SNPs associated with SCZ are shared with
bipolar disorder and autism, and recently some overlap between
SCZ and psychosis in AD was also observed in a large-scale
genome-wide association study.26 It is plausible that the genetic
sharing could extend from SNPs to CNVs.
We also identified duplications affecting three other genes,
including SET (chr 9), JAG2 (chr14) and ZFPM1 (chr16), which were
tentatively associated with AD+P as they did not achieve genome-
wide significance.
The protein encoded by SET, also named I2PP2A, is an
endogenous inhibitor of protein phosphatase-2A (PP2A), which
is a key protein phosphatase in dephosphorylating tau.48 SET is
widely expressed in different tissues and localizes primarily in the
nucleus.49 In AD brains, the compromised PP2A activity in
cytoplasm was shown to be caused by increased levels of SET
and its translocation from nucleus to the cytoplasm in
neurons.50–52 Transfection in PC12 cells53 demonstrated that SET
induces hyperphosphorylation of tau, suggesting that SET may
be involved in AD through the regulation of tau hyper-
phosphorylation. There is substantial evidence54 that AD+P is
associated with increased phosphorylated microtubule-associated
protein tau in the dorsolateral prefrontal cortex. This does
not go against our findings that frequency of this duplication in
AD+P (6.1%) was marginally lower (odds ratio = 0.44,
P= 1.95E− 06) than in AD intermediate P (16%) and AD+P
(17.6%). Though it is usually expected that full gene duplications
increase the gene expression/function, partial duplications may
lead to gene products with new functions or dysfunctional gene
products that would compete with and negatively regulate the
normal gene products.
Figure 3. Manhattan plot shows the genome-wide P-values for deletion CNVs associated with AD+P. This Manhattan plot demonstrates the
locations across the chromosomes of the human genome (horizontal axis) where associations between deletion calls at markers (dots) and AD
+P are shown using − log10 P-values (vertical axis). The higher the dots are, the stronger the genetic associations are. The strongest signals are
seen on chromosome 4 and chromosome 9. AD, Alzheimer's disease; CNV, copy-number variant; P, psychosis.
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JAG2, located on chr14 q32, was first identified as the human
brain expressed sequence tags homologous to Delta and
Serrate.55 Delta and Serrate are ligands of Notch receptor in
Drosophila, which can activate Notch and related receptors. Luo
et al.55 found that JAG2 was involved in human Notch1 pathway
of signal transduction. The Notch pathway is often regarded as a
developmental pathway, but Notch proteins and ligands are also
expressed and active in the adult brain. Notch is a key regulator of
adult neural stem cells, and involved in the regulation of
migration, morphology, synaptic plasticity and survival of imma-
ture and ageing neurons. Accumulated evidence shows that
aberrant Notch signaling contributes to the development of AD.56
Notch may be implicated in familial AD through interaction with
presenilin and APP in adult brain. Findings that Notch1 expression
was markedly elevated in AD brains in comparison with controls
raise the possibility that Notch1 has a role in terminally
differentiated neurons and AD.57–59
ZFPM1 (Zinc finger protein, FOG family member 1) is expressed
in human hematopoietic tissues as well as in adult cerebellum,
stomach, testis, lymph node, liver and pancreas.60 It has a role in
erythroid differentiation. The relationship between ZFPM1 and
psychiatric disorders is unknown.
We did not identify deletions that were genome-wide
significantly associated with AD+P. The strongest associated
deletions were located on chromosomes 4 and 9. The deletion
on chromosome 4 did not cover any known gene, while deletion
on 9p22.2 was nearby CNTLN (also named C9orf39). The latter was
an uncommon deletion that was present in 7 out of 440 AD+P
patients, but not in 136 AD− P or 593 AD intermediate P subjects.
CNTLN encodes a protein, called centlein, which was first identified
in rat brain.61 An aphidicolin-inducible common fragile site FRA9G
has been mapped to 9p22.2, within C9orf39 gene.62 Fragile sites
are regions of the genome that are prone to mutation and
epigenetic changes; hence, hot spots for genomic instability.
Common fragile sites are a component of normal chromosome
structure and are composed of unstable DNA stretches that form
gaps and breaks on metaphase chromosomes after partial
inhibition of DNA synthesis. Increasing evidence links genomic
and epigenomic instability, including multiple fragile sites regions
to neuropsychiatric diseases, including SCZ and autism.63 It has
been observed that fragile sites are more frequent in SCZ and co-
localize with SCZ-linked genes. Overlapping deletions in the
general population have been previously demonstrated at hg18
genomic position: 17 250 170–19 296 630 with frequency of 10 in
6533 subjects64 and at (hg18 genomic position: 17 226 376–17
367 629) with frequency 1 out of 1557 controls.65 More detailed
information on these deletions can be found in the database of
genomic variants66 (http://projects.tcag.ca/variation/).
In conclusion, using the Illumina HumanOmni1-Quad BeadChip,
we have identified a genome-wide significant duplication in the
APC2 gene on chromosome 19 associated with AD+P
(P= 7.2E− 10). We also found suggestive associations (Po5.0E−
6) of three other duplication loci in SET, JAG2 and ZFPM1. None of
the observed deletions were genome-wide significant. Our study
has identified novel susceptible genes for psychosis in AD and
suggests the possibility of extending the genetic sharing among
psychiatric disorders (for example, SCZ, autism and AD+P) from
SNPs to CNVs. However, the relationship of CNVs and the
functional activity of these genes need to be examined by
experiments. The interpretation of this study is also limited by the
lack of replication data; large-scale independent studies are
warranted to replicate the findings reported in this study.
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